



REQUEST FOR PROPOSALS

Frontotemporal Dementia Drug Discovery Program

The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Dementias (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this Request for Proposals (RFP).

Research investigating the pathologic mechanisms of neurodegeneration in frontotemporal dementia (FTD) and related disorders has advanced recently, creating new potential targets for drug discovery.

Examples of programs appropriate for this RFP include, but are not limited to:

- *Target validation studies*
- *Development and testing of novel high throughput screening assays*
- *Medicinal chemistry on lead compounds*
- *Identification and in vitro testing of potentially disease modifying lead compounds*
- *Testing of lead compounds in a relevant animal model for preclinical proof of concept*
- *ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds*
- *Development and testing of targeted gene delivery strategies*
- *Development of biomarkers to accelerate drug development and early diagnosis*
- *Innovative pilot clinical trials*

PLEASE NOTE: THIS FUNDING WILL NOT SUPPORT APPLICATIONS FOR BASIC RESEARCH

MECHANISM(S) OF SUPPORT

ADDF/AFTD will provide individual grants for one-year duration with the possibility of follow-on funding. Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Collaborative teams of neuroscientists and researchers in drug discovery disciplines such as medicinal chemistry and drug delivery are also encouraged to apply.

REVIEW PROCESS

The deadline date for applications is **October 1, 2009**. Applications will be confidentially reviewed by ADDF and an external Scientific Review Committee, including AFTD scientific advisors. Applications from biotechnology companies will also be reviewed by ADDF's external Business Advisory Board. Award winners will be publicly announced in Spring 2010.

APPLICATION PROCEDURE

ADDF and AFTD seek to work with prospective applicants to ensure appropriate and qualified programs of interest that meet their partnership objectives. An inquiry with ADDF scientific staff is therefore encouraged prior to application submission. To further discuss scientific or financial aspects of proposals, please contact:

Diana Shineman, PhD

Assistant Director for Scientific Affairs

Phone: 212-901-8007

E-mail: dshineman@alzdiscovery.org

All applications must be submitted electronically at www.alzdiscovery.org. For more information regarding the application process, please contact:

Adam Liebling

Senior Grants Manager

Phone: 212-901-8005

E-mail: aliebling@alzdiscovery.org

